Chemotherapies approved for defined subgroups promise personalized oncologic care, but their off-label impact is unclear. Lenalidomide is approved for lower-risk, transfusion-dependent (TD) myelodysplastic syndromes (MDS) with del(5q), but frequently used in MDS outside this indication. We characterized lenalidomide use and outcomes among non-TD patients with MDS.
| INTRODUCTION
Myelodysplastic syndromes (MDS) are myeloid malignancies characterized by ineffective clonal hematopoiesis, bone marrow dysplasia, and a risk of progression to acute myeloid leukemia (AML). [1] [2] [3] They are more common with advancing age, [4] [5] [6] [7] and although survival can be poor, there is considerable variability in outcomes. 8, 9 Disease risk is typically assessed using the International Prognostic Scoring System (IPSS) or Revised International Prognostic Scoring System (IPSS-R), which predict the risk of death and progression to AML. 10, 11 Patients with higher-risk disease typically receive hypomethylating agents (HMAs) azacitidine or decitabine 12, 13 or are considered for allogeneic stem cell transplantation. Those with lower-risk MDS, however, usually receive therapy directed toward alleviating cytopenia-related symptom burden and transfusion requirements. [14] [15] [16] [17] For lower-risk MDS, the thalidomide derivative lenalidomide can be effective in improving red blood cell (RBC) transfusion requirements, specifically among patients with a deletion of chromosome 5q. 18 This subgroup of patients have impressive responses to lenalidomide with nearly three quarters becoming transfusion independent (TI), compared with only approximately 25% of those without del (5q). 18, 19 It was on this basis that lenalidomide was approved by the New and emerging cancer therapies are increasingly focused on well-defined subsets of patients. 20 They can prove highly effective when a target is present, but may have significantly less activity and add toxicity and cost when used outside of the appropriate context. 21, 22 One such example is the poor response rate to EGFR inhibition for patients with non-small cell lung cancer (NSCLC) without EGFR mutations, 23, 24 and conversely, in the low response rates of EGFR-mutated NSCLC to checkpoint inhibition. 25 Lenalidomide for MDS, while not a targeted therapy per se, is most effective in a clearly-defined subgroup of patients with myelodysplastic syndromes and has clear transfusion response criteria, and as such provides a unique opportunity to study the real world use of an older medication approved for a specific malignancy subgroup. We sought to understand the usage patterns of lenalidomide, a therapy that primarily alters transfusion requirements, in transfusion-dependent and nontransfusion-dependent MDS patients in the United States.
| METHODS
We interrogated data provided by the National Cancer Institute's Sur- We excluded those patients with Medicare claims for lenalidomide but whose lenalidomide claims were more than 60 days prior to the time of reported MDS diagnosis in SEER (Supporting Information Figure S1 ).
Medicare part D claims were analyzed for evidence of lenalidomide use. CPT, HCPCS, and ICD-9 billing codes were used to characterize claims data related to transfusion requirements following an MDS diagnosis and related to toxicities associated with lenalidomide treatment, and to assess baseline disease risk utilizing the SEER- Characteristics of patients receiving lenalidomide were summarized descriptively, with differences by baseline TD status assessed using Wilcoxon rank-sum tests and Chi-square tests. Incident toxicities were compared between those with and without baseline TD using Chi-squared tests or Fisher's exact test when small cell counts (<5) were encountered.
For non-TD patients with MDS, we sought to characterize the association between receipt of lenalidomide and overall survival (OS).
Although lenalidomide may not impact transfusion needs for this subset, the impact of this chemotherapy on disease course and OS is unclear. We therefore compared non-TD patients receiving lenalidomide to matched controls who did not receive lenalidomide; we selected a landmark time of 6 months for this analysis, to allow us to define non-TD objectively from the date of initial MDS diagnosis for both patients who did and did not receive lenalidomide. Patients who died within 6 months post-MDS diagnosis were excluded. We identified the "exposed group" as patients who received lenalidomide within 6 months after an MDS diagnosis, were non-TD prior to initiating lenalidomide, and were alive within 6 months post-MDS diagnosis.
We matched one patient who did not receive lenalidomide ("unexposed group") to each exposed patient, using one-to-one nearest neighbor propensity score matching without replacement. Matching variables included SMMRS score-which incorporates a number of variables including patient age-as well as MDS histological subtype, HMA use within 6 months of MDS diagnosis, marital status, gender, total number of transfusions within 6 months of MDS diagnosis, SEER region, and year of diagnosis (Supporting Information Figure S1 ).
Finally, we evaluated OS starting at a landmark time of 6 months after MDS diagnosis between the exposed and unexposed groups; survival curves were estimated using the Kaplan-Meier method, and differences by receipt of lenalidomide were assessed using the Wilcoxon test because the survival curves deviated from proportional hazards, and the Wilcoxon places higher weight on earlier events. A sensitivity analysis was conducted among the subset of patients who were never transfusion dependent during this 6-month time frame. We then identified patients with MDS with confirmed del(5q), and performed a survival analysis of the subset of these patients who received lenalidomide at a time when they were not transfusion-dependent, comparing their OS to propensity-score matched controls with MDS with del(5q) but who did not receive lenalidomide.
We assessed response to lenalidomide for TD MDS patients. We included both patients with and without del(5q); in order to assess transfusion requirements relative to baseline, we excluded patients who had fewer than 8 weeks of claims data after initiation of lenalidomide. Primary endpoints for response were the proportion of patients who experienced TI or a 50% reduction in transfusions (minor response). Secondary endpoints for response included the time to TI and the duration of TI. Time to TI was defined as the number of days from the initiation of lenalidomide until the first day of the first 8-week transfusion-free period, as previously described. 18 Duration of TI was defined as the period from the day after the last transfusion until 1 day prior to the subsequent transfusion; patients who remained transfusion independent were censored at death or at the end of claims availability (December 31, 2014). The median duration of transfusion independence was estimated by the Kaplan-Meier method. All reported P-values are two-sided at the .05 significance level, and statistical analyses were conducted using SAS version 9.4.
| RESULTS
A total of 25 000 patients with MDS were enrolled in SEER between 2007 and 2013; of these, 12 933 met study inclusion criteria, including 676 who received lenalidomide, and 12 257 who did not have claims for lenalidomide (Supporting Information Figure S1 ).
| Characteristics of MDS patients receiving lenalidomide
The 676 patients who received lenalidomide for MDS included 275 (41%) who were TD, and 401 (59%) who were non-TD; 21% had MDS with del(5q), 35% had non-del(5q) MDS, and 43% had MDSUnspecified (Table 1 ). There was variation in the percentage of TD patients if more liberal definitions were used (Supporting Information Figure S2 ). For example, if TD was defined as a single claim for RBC transfusion within an 8-week period, the proportion of TD MDS patients increased to 66%; if an even more liberal definition of 1 RBC transfusion claim in the prior 6 months was used, 74% of MDS patients met TD criteria. Notably, a total of 18.5% of patients had no claims for any RBC transfusion prior to starting lenalidomide.
There was no significant difference in age at diagnosis, center volume, race, SEER region, or marital status between TD and non-TD patients (Table 1) . Non-TD patients overall had lower-risk disease by SMMRS (P = .0001), expected since the SMMRS incorporates transfusions as part of its risk calculation. TD patients had a longer time to initiation of lenalidomide after MDS diagnosis (median 266 days vs. 98 days, P < .0001). TD patients also had higher claim rates of thrombocytopenia, neutropenia, prior HMA use, and prior growth factor use preceding the use of lenalidomide.
A total of 143 patients had MDS with del(5q) confirmed in SEER and were treated with lenalidomide; 47 (33%) of these patients were TD while 96 (67%) were non-TD (Supporting Information Table S1 ).
Patients with MDS with del(5q) who were TD, compared with patients with MDS with del(5q) but who were non-TD, had significantly higher risk disease by SMMRS (P = .006), and were more likely to have baseline thrombocytopenia (P = .006), and prior HMA or growth factor use. The subset of patients with MDS with del(5q) received lenalidomide closer to diagnosis (77 days for TD and 46.5 days for non-TD patients) relative to the overall group of MDS patients (266 and 98 days, respectively).
Among all TD and non-TD patients, the majority received lenalidomide in the first-line setting; a total of 175 patients (26%) received lenalidomide after previously receiving HMA therapy. The median number of claims for lenalidomide on unique dates, a measure of duration of therapy, for TD patients was 2 (IQR: 1,5) while the median for non-TD patients was 4 claims (IQR: 2,9).
| Outcomes of MDS patients receiving lenalidomide
Toxicities putatively associated with lenalidomide were assessed using claims 27 for incident complicating events within 180 days after starting therapy ( Table 2 ). The most frequent complications included cytopenias; there were also high (>20%) incident rates of dyspnea, fatigue, arthralgias, peripheral neuropathy, and fevers. Incident toxicities were similar within the subgroup of patients with MDS with del (5q) (Supporting Information Table S2 ). There were claims for incident thromboembolic events in 6.0% of the TD patients on lenalidomide, and 10.8% of non-TD patients (P = .04). Within the subgroup of patients with MDS with del(5q), 9.3% of the TD patients had a VTE claim compared with 12.9% of the non-TD patients (P = .55). Of the 401 non-TD patients receiving lenalidomide, 217 (54%) subsequently met TD criteria during treatment.
We identified 191 non-TD patients with MDS who had received lenalidomide within 6 months of MDS diagnosis and who survived at least 6 months post-diagnosis, and matched these patients 1:1 with 191 patients with MDS who had never received lenalidomide (Supporting Information Table S3 ). Of the group of non-TD patients given lenalidomide, 36% reported MDS with del(5q), the majority were female (64%), and most (83%) had not previously received HMA Table S4 ). Compared with a propensity-score matched cohort of 68 non-TD patients with MDS with del(5q) who did not receive lenalidomide, there was no significant improvement in overall survival (P = .60, Figure 1B) , similar to what was seen with the overall non-TD MDS population. 
| DISCUSSION
In this large cohort of patients with MDS, we found that lenalidomide is frequently prescribed to patients who would not typically meet study criteria for transfusion dependence, as they were initiated on therapy without having at least 2 transfusions within an 8-week period. In clinical practice, some may initiate lenalidomide when patients require transfusions but may not fully reach this threshold; however, even when we evaluated different definitions of transfusion dependence, approximately 18% of patients receiving lenalidomide had never previously been transfused. That we also found significant incident toxicities among those non-TD patients receiving lenalidomide without a corresponding survival benefit suggests that the basis for use of lenalidomide in non-TD MDS patients is potentially deleterious.
Although lenalidomide is most effective in a distinct clinical subgroup-patients with lower-risk MDS with del(5q) who are transfusion dependent-it has some efficacy in the non-del(5q) transfusiondependent population, 28 and it is not unreasonable to trial this agent found that over half of the non-TD patients with MDS started on lenalidomide will nonetheless subsequently meet TD criteria while still on therapy, whether due to disease progression or related to receiving lenalidomide, and that there is no improvement in overall survival for those patients who are not TD but nonetheless start lenalidomide early after the diagnosis of MDS.
Lenalidomide has a number of putative mechanisms of action in MDS, including immunomodulatory and direct pro-apoptotic effects, that may impact more than erythropoiesis. [30] [31] [32] Nonetheless, the role of lenalidomide for patients with no or few transfusion needs is unclear, [33] [34] [35] and associated with expected toxicities, as shown in the current analysis. We, therefore, explored whether, patients based on genetic, disease, and clinical characteristics. 36 How these therapies will be incorporated into clinical practice, and whether clinical trial successes will translate into population survival improvements, remains to be seen.
More challenging are patients subsets with differential responses that are non-binary; for instance, the response to PD-1 directed therapy in tumors with varying levels of PD-L1 expression. 37, 38 Similarly to MDS with or without del(5q), tumor PD-L1 expression identifies groups more or less likely to respond to checkpoint blockade, but it does not provide perfect discrimination between responders and nonresponders. The experience we report with lenalidomide suggests that treatments approved for a specific subgroup of patients are often used off-label. While lenalidomide usage in certain unique scenarios may be reasonable, a non-trivial proportion of treated patients may be distinctly inappropriate for lenalidomide therapy.
We chose to utilize the linked SEER-Medicare database to take advantage of the strengths of each dataset; SEER reports MDS cases with high accuracy of diagnosis and has robust survival data, and
Medicare claims effectively capture transfusion events, a primary outcome of interest. There are limitations to these data sources, however. 
